PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Long and short noncoding RNAs in lung cancer precision medicine: Opportunities and challenges.

Abstract The long and short noncoding RNAs have been involved in the molecular diagnosis, targeted therapy, and predicting prognosis of lung cancer. Utilizing noncoding RNAs as biomarkers and systemic RNA interference as an innovative therapeutic strategy has an immense likelihood to generate novel concepts in precision oncology. Targeting of RNA interference payloads such as small interfering RNAs, microRNA mimetic, or anti-microRNA (antagomirs) into specific cell types has achieved initial success. The clinical trials of noncoding RNA-based therapies are on the way with some positive results. Many attempts are done for developing novel noncoding RNA delivery strategies that could overcome systemic or local barriers. Furthermore, it precipitates concerted efforts to define the molecular subtypes of lung cancer, characterize the genomic landscape of lung cancer subtypes, identify novel therapeutic targets, and reveal mechanisms of sensitivity and resistance to targeted therapies. These efforts contribute a visible effect now in lung cancer precision medicine: patients receive molecular testing to determine whether their tumor harbors an actionable come resistance to the first-generation drugs are in clinical trials, and drugs targeting the immune system are showing activity in patients. This extraordinary promise is tempered by the sobering fact that even the newest treatments for metastatic disease are rarely curative and are effective only in a small fraction of all patients. Thus, ongoing and future efforts to find new vulnerabilities of lung cancers unravel the complexity of drug resistance, increase the efficacy of immunotherapies, and perform biomarker-driven clinical trials are necessary to improve the outcome of lung cancer patients.
PMID
Related Publications

The pseudogene-derived long noncoding RNA SFTA1P is down-regulated and suppresses cell migration and invasion in lung adenocarcinoma.

Long Noncoding RNAs in Lung Cancer.

The Emerging Role and Promise of Long Noncoding RNAs in Lung Cancer Treatment.

Harnessing RNAi nanomedicine for precision therapy.

Lung cancer in the era of precision medicine.

Authors

Mayor MeshTerms

Precision Medicine

Keywords

Precision medicine

long noncoding RNA

lung cancer

microRNA

small interfering RNA

targeted therapy

Journal Title tumour biology : the journal of the international society for oncodevelopmental biology and medicine
Publication Year Start




PMID- 28381159
OWN - NLM
STAT- MEDLINE
DA  - 20170406
DCOM- 20170418
LR  - 20170418
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Linking)
VI  - 39
IP  - 4
DP  - 2017 Apr
TI  - Long and short noncoding RNAs in lung cancer precision medicine: Opportunities
      and challenges.
PG  - 1010428317697578
LID - 10.1177/1010428317697578 [doi]
AB  - The long and short noncoding RNAs have been involved in the molecular diagnosis, 
      targeted therapy, and predicting prognosis of lung cancer. Utilizing noncoding
      RNAs as biomarkers and systemic RNA interference as an innovative therapeutic
      strategy has an immense likelihood to generate novel concepts in precision
      oncology. Targeting of RNA interference payloads such as small interfering RNAs, 
      microRNA mimetic, or anti-microRNA (antagomirs) into specific cell types has
      achieved initial success. The clinical trials of noncoding RNA-based therapies
      are on the way with some positive results. Many attempts are done for developing 
      novel noncoding RNA delivery strategies that could overcome systemic or local
      barriers. Furthermore, it precipitates concerted efforts to define the molecular 
      subtypes of lung cancer, characterize the genomic landscape of lung cancer
      subtypes, identify novel therapeutic targets, and reveal mechanisms of
      sensitivity and resistance to targeted therapies. These efforts contribute a
      visible effect now in lung cancer precision medicine: patients receive molecular 
      testing to determine whether their tumor harbors an actionable come resistance to
      the first-generation drugs are in clinical trials, and drugs targeting the immune
      system are showing activity in patients. This extraordinary promise is tempered
      by the sobering fact that even the newest treatments for metastatic disease are
      rarely curative and are effective only in a small fraction of all patients. Thus,
      ongoing and future efforts to find new vulnerabilities of lung cancers unravel
      the complexity of drug resistance, increase the efficacy of immunotherapies, and 
      perform biomarker-driven clinical trials are necessary to improve the outcome of 
      lung cancer patients.
FAU - Tian, Haihua
AU  - Tian H
AD  - 1 Department of Biochemistry and Molecular Biology, Ningbo University School of
      Medicine, Ningbo, China.
AD  - 2 Zhejiang Provincial Key Laboratory of Pathophysiology, Ningbo University School
      of Medicine, Ningbo, China.
AD  - 3 Department of Laboratory Medicine, Ningbo Kangning Hospital, Ningbo, China.
FAU - Zhou, Chengwei
AU  - Zhou C
AD  - 4 Department of Thoracic Surgery, The Affiliated Hospital of Ningbo University
      School of Medicine, Ningbo, China.
FAU - Yang, Jie
AU  - Yang J
AD  - 1 Department of Biochemistry and Molecular Biology, Ningbo University School of
      Medicine, Ningbo, China.
AD  - 2 Zhejiang Provincial Key Laboratory of Pathophysiology, Ningbo University School
      of Medicine, Ningbo, China.
FAU - Li, Jingqiu
AU  - Li J
AD  - 1 Department of Biochemistry and Molecular Biology, Ningbo University School of
      Medicine, Ningbo, China.
AD  - 2 Zhejiang Provincial Key Laboratory of Pathophysiology, Ningbo University School
      of Medicine, Ningbo, China.
FAU - Gong, Zhaohui
AU  - Gong Z
AD  - 1 Department of Biochemistry and Molecular Biology, Ningbo University School of
      Medicine, Ningbo, China.
AD  - 2 Zhejiang Provincial Key Laboratory of Pathophysiology, Ningbo University School
      of Medicine, Ningbo, China.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental
      Biology and Medicine
JID - 8409922
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (RNA, Small Untranslated)
SB  - IM
MH  - Clinical Trials as Topic
MH  - Drug Resistance, Neoplasm
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/genetics/prevention & control
MH  - *Precision Medicine
MH  - RNA Interference
MH  - RNA, Long Noncoding/*administration & dosage/physiology
MH  - RNA, Small Untranslated/*administration & dosage/physiology
OTO - NOTNLM
OT  - *Precision medicine
OT  - *long noncoding RNA
OT  - *lung cancer
OT  - *microRNA
OT  - *small interfering RNA
OT  - *targeted therapy
EDAT- 2017/04/07 06:00
MHDA- 2017/04/19 06:00
CRDT- 2017/04/07 06:00
AID - 10.1177/1010428317697578 [doi]
PST - ppublish
SO  - Tumour Biol. 2017 Apr;39(4):1010428317697578. doi: 10.1177/1010428317697578.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>